Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: AZD9550 and AZD6234 in Obesity or Overweight
NCT06862791Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Primary completion
- May 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of AZD9550 and lenbelintide in obesity and Overweight (9 arms), sponsored by AstraZeneca. Primary endpoints: Percent change in body weight from baseline at 36 weeks and Weight loss >= 5% from baseline at 36 weeks. Started Feb 2025; status: completed.
02
Drugs
AZD9550lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06862791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06862791.